Inventor · disambiguated record
Ehab Hamed
Also filed as: HAMED EHAB
9 granted patents·18 pending applications·74 citations·filing 2007–2025
87Inventor score
Top patents by PatentIndex Score
27 records- 0195US10568937B2Formulations of abaloparatide, transdermal patches thereof, and uses thereofRADIUS HEALTH INC·Filed 2017·Granted Feb 25, 2020·17 cites·7 claims
- 0294US10980862B2Formulations of abaloparatide, transdermal patches thereof, and uses thereofRADIUS HEALTH INC·Filed 2020·Granted Apr 20, 2021·5 cites·18 claims
- 0393US9216176B2Abuse resistant drug formulationCIMA LABS INC·Filed 2015·Granted Dec 22, 2015·8 cites·14 claims
- 0493US8445018B2Abuse resistant drug formulationHABIB WALID A·Filed 2008·Granted May 21, 2013·38 cites·16 claims
- 0580US2025205161A1Formulations of vimseltinibDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 0679US9572803B2Abuse resistant drug formulationCIMA LABS INC·Filed 2012·Granted Feb 21, 2017·1 cites·4 claims
- 0777US9474721B2Abuse-resistant formulationsCIMA LABS INC·Filed 2014·Granted Oct 25, 2016·1 cites·12 claims
- 0877US8927025B2Alcohol-resistant metoprolol-containing extended-release oral dosage formsHAMED EHAB·Filed 2011·Granted Jan 6, 2015·4 cites·5 claims
- 0975US12447149B2Formulations of vimseltinibDECIPHERA PHARMACEUTICALS LLC·Filed 2025·Granted Oct 21, 2025·0 cites·22 claims
- 1073US2023277444A1FORMULATIONS OF PTHrP ANALOGUES, TRANSDERMAL PATCHES THEREOF, AND USES THEREOFRADIUS HEALTH INC·Filed 2022·Application pending·0 cites
- 1171US2019099417A1Abuse resistant drug formulationCIMA LABS INC·Filed 2018·Application pending·0 cites
- 1269US2018303826A1Abuse resistant drug formulationCIMA LABS INC·Filed 2018·Application pending·0 cites
- 1368US2025195487A1Formulations of a csf-1r inhibitorDECIPHERA PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 1466US2021369816A1Formulations of abaloparatide, transdermal patches thereof, and uses thereofRADIUS HEALTH INC·Filed 2021·Application pending·0 cites
- 1565US2008031949A1High dose orally dissolvable/disintegrable lyophilized dosage formCIMA LABS INC·Filed 2007·Application pending·0 cites
- 1661US2008031947A1Orally dissolvable/disintegrable lyophilized dosage forms containing protectedCIMA LABS INC·Filed 2007·Application pending·0 cites
- 1759US2019133924A1Alcohol-Resistant FormulationsCIMA LABS INC·Filed 2019·Application pending·0 cites
- 1857US2008069891A1Abuse resistant drug formulationCIMA LABS INC·Filed 2007·Application pending·0 cites
- 1955US2021379162A1Transdermal system for the delivery of abaloparatide and method of use for treating osteoporosisRADIUS HEALTH INC·Filed 2021·Application pending·0 cites
- 2050US9974751B2Abuse resistant drug formulationCIMA LABS INC·Filed 2012·Granted May 22, 2018·0 cites·6 claims
- 2150US2012225122A1Abuse-Resistant FormulationsHAMED EHAB·Filed 2012·Application pending·0 cites
- 2247US2013202705A1Alcohol-resistant formulationsHAMED EHAB·Filed 2011·Application pending·0 cites
- 2344US2011200681A1Abuse Resistant Drug FormulationCIMA LABS INC·Filed 2011·Application pending·0 cites
- 2444US2018049974A1Abuse-resistant formulationsCIMA LABS INC·Filed 2017·Application pending·0 cites
- 2543US2013209560A1Abuse-resistant formulationsHAMED EHAB·Filed 2011·Application pending·0 cites
- 2640US2019091138A1Formulations of pthrp analogues, transdermal patches thereof, and uses thereofRADIUS HEALTH INC·Filed 2018·Application pending·0 cites
- 2738US2013171256A1Alcohol-resistant extended release dosage forms comprising venlafaxineHAMED EHAB·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ehab Hamed files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →